Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome-Reference-Cited by-同舟云学术

Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

Published:2017-10-02 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Bala Malgorzata M¹,Celinska-Lowenhoff Magdalena²,Szot Wojciech³,Padjas Agnieszka²,Kaczmarczyk Mateusz⁴,Swierz Mateusz J⁵,Undas Anetta⁶

Affiliation:

1. Jagiellonian University Medical College; Chair of Epidemiology and Preventive Medicine; Department of Hygiene and Dietetics; Systematic Reviews Unit; Kopernika 7 Krakow Poland 31-034

2. Jagiellonian University Medical College; 2nd Department of Internal Medicine, Department of Allergy and Immunology; Skawinska 8 Krakow Poland 31-066

3. Jagiellonian University Medical College; Department of Hygiene and Dietetics; Krakow Poland

4. Jagiellonian University Medical College; Systematic Reviews Unit - Polish Cochrane Branch; Krakow Poland

5. Jagiellonian University Medical College; Department of Hygiene and Dietetics, Systematic Reviews Unit; Krakow Poland

6. Jagiellonian University Medical College; Institute of Cardiology; Pradnicka 80 Krakow Poland 31-202

Publisher

Wiley

Subject

Pharmacology (medical)

Reference101 articles.

1. A randomized trial of two intensities of warfarin (international normalized ratio of 2.0 to 3.0 versus 3.1 to 4.0) for the prevention of recurrent thrombosis in patients with antiphospholipid antibodies;Crowther;Blood,2002

2. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome;Crowther;New England Journal of Medicine,2003

3. Comparison between single antiplatelet therapy and combination of anti-platelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome;Okuma;International Journal of Medical Sciences,2010

4. Okuma H lijima K Goto Y Yasuda T Tokuoka K Kitagawa Y Prevention in ischemic stroke with antiphospholipid syndrome Proceedings of the International Stroke Conference 2013. 6-8 February 2013; Honolulu, Hawaii, USA 2013

5. 2012-002345-38 A prospective randomised controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE www.clinicaltrialsregister.eu/ctr-search/trial/2012-002345-38/GB/

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances of oxidative stress in thromboangiitis obliterans: biomolecular mechanisms, biomarkers, sources and clinical applications;Thrombosis Research;2023-10

2. Antithrombotic therapy in antiphospholipid syndrome with arterial thrombosis: a systematic review and network meta-analysis;Frontiers in Medicine;2023-06-15

3. Comparing the efficacy and safety of direct oral anticoagulants versus Vitamin K antagonists in patients with antiphospholipid syndrome: a systematic review and meta-analysis;Blood Coagulation & Fibrinolysis;2022-07-22

4. Gastrointestinal symptoms as the first manifestation of antiphospholipid syndrome;BMC Gastroenterology;2021-04-01

5. Direct oral anticoagulants in patients with antiphospholipid syndrome;Blood Coagulation & Fibrinolysis;2021-02-09